JB 111
Alternative Names: JB-111Latest Information Update: 21 Jul 2025
At a glance
- Originator Jaya Biosciences
- Class Antidementias; Gene therapies; Neuroprotectants
- Mechanism of Action Gene transference; Palmitoyl-protein thioesterase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Alzheimer's disease; Neurodegenerative disorders
Highest Development Phases
- Preclinical Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 16 Jul 2025 JB 111 is available for licensing in Asia as of 16 Jul 2025. https://www.jayabio.com/contact
- 12 Jul 2025 Jaya Biosciences receives patent allowance for novel methods of treating Neurodegenerative disorders, including Alzheimer’s disease in China
- 10 Jul 2025 Jaya Biosciences receives patent allowance for novel methods of treating Neurodegenerative disorders, including Alzheimer’s disease in Japan